View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Abbott Laboratories: Update to credit analysis

Our credit view of this issuer reflects its significant scale and global operations, against its commitment to significant shareholder distributions.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Abbott Laboratories: Key Facts and Statistics - LTM September 2023

A summary company profile, detailing Abbott Laboratories’s business operations and financial highlights.

Abbott Laboratories: 1 director

A director at Abbott Laboratories sold 50,000 shares at 94.051USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...

Abbott Laboratories - June 2023 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Abbott Laboratories: Update to credit analysis following upgrade to Aa...

Our credit view of this issuer reflects its significant scale, diversity and global operations, against its commitment to significant shareholder distributions.

Abbott Laboratories: Update to credit analysis

Our credit view of this issuer reflects its significant scale, global operations and diversified product portfolio, partially mitigated by covid-19 testing revenues that will decline in 2023

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Abbott Laboratories: Update to credit analysis

Our credit view of this issuer reflects its leading market position.

Abbott Laboratories: Update to credit analysis following upgrade to A1

Our credit view of this issuer reflects its significant scale and global operations, against its commitment to significant shareholder distributions.

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch